Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 7

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 7
---
 this offering*:

| Book value per share before offering       
 Book value per share after offering        
 Net increase to original shareholders      |     | 10% | (0.05 
 (0.05 
 (0.00 | ) 
 ) 
 ) |     | 25% | (0.05 
 (0.04 
 (0.01 | ) 
 ) 
 ) |     | 50% | (0.05 
 (0.03 
 (0.02 | ) 
 ) 
 ) |     | 75% | (0.05 
 (0.03 
 (0.02 | ) 
 ) 
 ) |     | 100% | (0.05 
 (0.02 
 (0.03 | ) 
 ) 
 ) |
|:-------------------------------------------|:----|:----|------:|:--|:----|:----|------:|:--|:----|:----|------:|:--|:----|:----|------:|:--|:----|:-----|------:|:--|
| Decrease in investment to new shareholders |     | $   |  0.06 |   |     | $   |  0.05 |   |     | $   |  0.04 |   |     | $   |  0.04 |   |     | $    |  0.03 |   |
| Dilution percentage to new shareholders    |     |     | 30.00 | % |     |     | 25.00 | % |     |     | 20.00 | % |     |     | 20.00 | % |     |      | 15.00 | % |

* Based on book value as of 6/30/2025.

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below as well as other information provided to you in this Offering Circular, including information in the section of this document entitled “CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS”. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our common stock could decline, and you may lose all or part of your investment. The following discussion and analysis should be read in conjunction with the other financial information and consolidated financial statements and related notes appearing in this Offering Circular.

Risks Related